

Name of the Issue: Vijaya Diagnostic Centre Limited

1 Type of Issue Initial Public Offer

2 Issue Size (Rs. Mn) 18,924.56*

**Source: Prospectus*

3 Grade of issue along with name of the rating agency

Name Not Applicable

Grade Not Applicable

4 Subscription Level (Number of times) 3.30*

Source: Basis of allotment

5 QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment *	30.94%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2021)	39.25%
(iii) at the end of 1st FY (March 31, 2022)	41.20%
(iv) at the end of 2nd FY (March 31, 2023)	39.48%
(v) at the end of 3rd FY (March 31, 2024)**	N.A.

**Shareholding pattern disclosed to Stock Exchanges*

*** QIB Holding not disclosed as reporting for relevant period has not been completed.*

6 Financials of the issuer

(Rs. Million)

Parameters	1st FY (March 31, 2022)	2nd FY (March 31, 2023)	3rd FY (March 31, 2024)
Income from operations	4,623.70	4,733.73	5,478
Net Profit for the period	1,106.68	852.07	1,196
Paid-up equity share capital	101.97	102.07	102
Reserves / Other Equity	4,580.23	5,345.22	6,470

7 Trading Status

The equity shares of the Company are listed on BSE Limited ("**BSE**") and National Stock Exchange of India Limited ("**NSE**")
The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2024) *	Frequently traded

Source: Stock exchange data.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	Nishant Sharma	Resignation
(ii) at the end of 2nd FY (March 31, 2023)	Sura Suprita Reddy	Appointed
(iii) at the end of 3rd FY (March 31, 2024)	Sura Suprita Reddy	Appointed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable as 100% offer for sale
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	Not applicable as 100% offer for sale
(ii) Actual utilization	Not applicable
(iii) Reasons for deviation, if any	Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	531.00
Listing Date	14-Sep-21

Price parameters	At close of listing day- 14-Sep-2021	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2022)		
				Closing price	High	Low
Market Price	620.10	559.75	573.90	438.2	644.1	379.2
Nifty (since NSE is the designated exchange)	17,380.00	18,161.75	17,511.30	17,464.8	18,477.1	14,296.4
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2023)			As at the end of the 3rd FY after the listing of the issue (31st March, 2024)		
	Closing price	High	Low	Closing price	High	Low
Market Price	391.30	489.35	300.40	636.60	718.80	349.25
Nifty	17,359.75	18,812.50	15,293.50	22,326.90	22,526.60	17,312.75

13 Basis for Issue Price

Accounting ratio	As disclosed in offer document, at the end of FY 2021*	At the end of 1st FY (March 31, 2022)	At the end of 1st FY (March 31, 2023)	At the end of 1st FY (March 31, 2024)
EPS (Basic)	Company			
	Consolidated	8.26	10.76	8.16
	Peer Group & Industry Avg	35.65	41.79	28.37
	Dr. Lal Pathlabs	35.33	41.70	28.82
	Metropolis Healthcare Limited	35.97	41.87	27.91
P/E	Company			
	Consolidated	64.29	40.72	47.95
	Peer Group & Industry Avg^	90.85	55.61	54.08
	Dr. Lal Pathlabs	107.30	62.61	63.43
	Metropolis Healthcare Limited	74.40	48.62	44.73

RoNW	Company				
	Consolidated	23.64%	24%	15.64%	18.20%
	Peer Group & Industry Avg	24.67%	0.13	14.49%	15.66%
	Dr. Lal Pathlabs	23.42%	23%	14.47%	19.59%
	Metropolis Healthcare Limited	25.91%	2%	14.51%	11.72%
NAV per share	Company				
	Consolidated	35.23	46.09	53.37	64.24
	Peer Group & Industry Avg	143.81	956.36	196.42	217.68
	Dr. Lal Pathlabs	149.38	180.93	199.87	221.47
	Metropolis Healthcare Limited	138.23	1,731.78	192.97	213.88

Notes

* Sourced from Prospectus

^ P/E is calculated as closing market price on NSE as on March 31, 2021 / Basic EPS for the year ended March 31, 2021 sourced from the Prospectus

14 Any other material information

Particulars	Date
Listing of equity shares of Vijaya Diagnostic Centre Ltd	14-Sep-21
Un-Audited Financial Results For The Second Quarter And Half Year Ended September 30, 2021.	8-Nov-21
Appointment of Company Secretary and Compliance Officer	8-Nov-21
Board Meeting Outcome for Outcome Of Board Meeting Held On November 8, 2021	8-Nov-21
Board Meeting Outcome for Outcome Of Board Meeting Held On February 4, 2022	4-Feb-22
Announcement under Regulation 30 (LODR)-Cessation	8-Mar-22
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended March 31,	26-May-22
Vijaya Diagnostic Centre Limited has informed the Exchange that Record date for the purpose of Dividend is 21-Sep-	30-Aug-22
Intimation Of Record Date For The Final Dividend For The Financial Year 2021-22	30-Aug-22
Unaudited Financial Results For The Second Quarter And Half Year Year Ended September 30, 2022	10-Nov-22
Announcement under Regulation 30 (LODR)-Change in Registered Office Address	10-Nov-22
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer	10-Nov-22
Clarification sought from Vijaya Diagnostic Centre Ltd	22-Dec-22
Appointment of Company Secretary and Compliance Officer	22-Dec-22
Unaudited Financial Results For The Quarter And Nine Months Ended 31st December 2022	13-Feb-23
Appointment of Company Secretary and Compliance Officer	13-Feb-23
Clarification sought from Vijaya Diagnostic Centre Ltd	28-Mar-23
Clarification On Increase In Volume	28-Mar-23
Clarification sought from Vijaya Diagnostic Centre Ltd	28-Apr-23
Clarification On Increase In Volume	28-Apr-23
Financial Results For The Q4 & FY 2023 (Standalone & Consolidated)	29-Apr-23
Corporate Action-Board approves Dividend	29-Apr-23
Announcement under Regulation 30 (LODR)-Change in Directorate	29-Apr-23
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s	29-Apr-23
Re-Appointment Of Cost Auditors Of The Company For The FY 2023-2024	29-Apr-23
Financial Results For The Q4 & FY 2023 (Standalone & Consolidated)	29-May-23
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s	29-May-23
Re-Appointment Of Cost Auditors Of The Company For The FY 2023-2024	29-May-23
Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended June 30, 2023	9-Aug-23
Appointment Of Secretarial Auditor For The FY 2023-24	9-Aug-23
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	22-Aug-23
Corporate Action - Record Date Fixed For Wednesday, 13Th September 2023 For Dividend Payment	28-Aug-23

Shareholder Meeting / Postal Ballot-Outcome of AGM	20-Sep-23
Announcement under Regulation 30 (LODR)-Change in Management	22-Sep-23
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditors	22-Sep-23
Awareness On Online Dispute Resolution (ODR) Mechanism.	19-Oct-23
Announcement under Regulation 30 (LODR)-Allotment	3-Nov-23
Unaudited Financial Results For The Second Quarter And Half Year Ended 30Th Sep 2023	7-Nov-23
Clarification sought from Vijaya Diagnostic Centre Ltd	6-Dec-23
Announcement under Regulation 30 (LODR)-Acquisition	19-Dec-23
Announcement under Regulation 30 (LODR)-Updates on Acquisition	21-Dec-23
Update On Subsidiaries	18-Jan-24
Board Meeting Intimation for Quarterly Results	21-Jan-24
Board Meeting Outcome for Outcome Of The Board Meeting Held On 05Th Feb 2024	5-Feb-24
Announcement under Regulation 30 (LODR)-Allotment	6-Feb-24
Update On Subsidiaries	8-Apr-24
Announcement under Regulation 30 (LODR)-Allotment	3-May-24

Note: For further updates and information, please refer Stock Exchange websites